The CARDIO-TTRansform trial investigating eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy did not meet its primary efficacy endpoint, according to results presented in a Hot Line session at ESC Congress 2026.
source https://medicalxpress.com/news/2026-08-eplontersen-trial-primary-endpoint-transthyretin.html
source https://medicalxpress.com/news/2026-08-eplontersen-trial-primary-endpoint-transthyretin.html
Comments
Post a Comment